Cypress pricing is simple and transparent, with no surprises
For maximizing weight loss, dual agonists are better
Lindsay CR, Lawn S, Campbell AD, Faller WJ, Rambow F, Mort RL et al
10 FriesnerR
STEP Clinical Trial Program The landmark STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program represents the most extensive investigation of semaglutide for weight management: STEP 1 (New England Journal of Medicine): Enrolled 1,961 adults with obesity or overweight and demonstrated a mean weight loss of 14.9% from baseline at 68 weeks with semaglutide 2.4 mg compared to 2.4% with placebo
Peters U, Suratt BT, Bates JHT, Dixon AE (2018) Beyond BMI: obesity and lung disease